Only 7% of Therapy Practices Track What They Say Defines Success, New Ensora Health Research Finds

Ensora Health’s 2026 Practice Success Report (surveying 1,124 therapists) finds only 18% of therapy practices describe themselves as “thriving,” despite 95% saying outcomes, financial health, operations, clinician well-being, and client experience all matter. The report highlights large measurement gaps—only 7% track all five domains and 68% lack reliable visibility into why clients stop treatment early—while “Thrivers” follow up after early exits more often (44% vs 26%). The release is accompanied by a conference session at APA 2026 and promotes Ensora’s low-lift framework (one metric tracked weekly, no new paperwork), positioning the company as a solution for practice performance measurement and operations.

Analysis

The actionable read-through is not demand for therapy software per se, but proof that the addressable market is fragmented, under-measured, and operationally leaky. That typically favors vendors that sit in the workflow and can prove ROI fast: billing, scheduling, outcomes capture, and AI-assisted documentation. The economics are best for platforms that reduce no-shows and improve collections, because those benefits are immediately visible to SMB buyers and can justify seat-based or transaction-based pricing.

The second-order loser is the point-solution stack. If owners already feel overloaded, adding another dashboard has weak adoption unless it removes labor or captures revenue. That argues for bundled systems and against standalone analytics names that need behavioral change to monetize. For public equities, the near-term earnings impact is likely negligible; any benefit should show up only over 2-4 quarters in lower churn, higher ARPU, or better net retention at vertical SaaS vendors.

Contrarian view: the market may overestimate the willingness of small practices to pay for “measurement” versus simply tolerating leakage. This is more a retention/product-marketing message than a hard budget catalyst. The thesis is falsified if vendors servicing this cohort do not show better bookings or retention by the next two reporting cycles; absent that, the report is noise, not signal.

Key Decisions for Investors

• Stay flat GOOGL for the next 1-3 months; this release does not create a measurable cloud/ads catalyst. Falsify only if management later ties healthcare workflow/AI product demand to incremental bookings.
• Do not initiate positions in HIT, MDCE, or TSTS on this press release alone. These names need proof of conversion in the next earnings print (bookings, NRR, or churn) before they become investable.
• If you want exposure, wait for a confirmation setup in the next 1-2 quarters: buy a healthcare workflow/RCM basket on evidence of improved collections or retention, and fund it by shorting weaker point-solution software once margins or churn data deteriorate.
• Use any 3%-5% post-release pop in the most illiquid names as a fade opportunity only if volume is thin and no guidance revision follows; stop out on a further 2%-3% move higher.